MBRX — Moleculin Biotech Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- $28.91m
- -$21.48m
- 42
- 49
- 41
- 41
Annual cashflow statement for Moleculin Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.8 | -11.9 | -13.2 | -17.4 | -15.9 |
| Depreciation | |||||
| Non-Cash Items | 1.92 | -2 | -2.05 | -0.575 | -4.26 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.542 | 1.61 | -2.14 | -0.041 | 1.04 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.32 | -12.2 | -17.2 | -17.8 | -19 |
| Capital Expenditures | -0.028 | -0.417 | -0.052 | -0.376 | -0.019 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | 0.001 | 0.002 | 0 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.028 | -0.417 | -0.051 | -0.374 | -0.019 |
| Financing Cash Flow Items | — | — | — | -0.017 | -0.023 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.1 | 12 | 20.9 | 22.5 | 74.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.71 | -0.58 | 3.6 | 4.44 | 55.7 |